Stand Up To Cancer formed three teams investigating treatments for Non-Small Cell Lung Cancer and Ewing sarcoma, including a Lung Cancer Health Equity SU2C Catalyst Research Team with support from Bristol Myers Squibb and two SU2C Catalyst Research Teams with support from Jazz Pharmaceuticals.
As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease. The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...
